COMPASS Pathways plc Q3 2026 Earnings Recap

Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties.

Key Takeaways

• Compass expects to complete its rolling NDA submission within two weeks, supported by two Phase III studies and a Phase IIb study that together enrolled more than 1,000 patients.
• The National Priority Voucher sets a one-to-two-month FDA review target, but the company described approval as a possibility, not a certainty.
• Compass reported $444 million in cash as of September 30 and said it expects funds to carry it through launch and into 2028.
• Commercial preparations continue: non-field commercial roles are filled, hiring for the field force is underway, and payer and clinician engagement is ongoing.
• The registrationally designed PTSD trial is actively enrolling; Compass cited PTSD as a potential label expansion opportunity alongside its TRD launch focus.